Experienced in Hemochromatosis

Dr. Biree Andemariam

Hematology Oncology | Hematology | Oncology
University Of Connecticut Health Center
263 Farmington Ave, 
Farmington, CT 
Experienced in Hemochromatosis
University Of Connecticut Health Center
263 Farmington Ave, 
Farmington, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Biree Andemariam is a Hematologist Oncology specialist and a Hematologist in Farmington, Connecticut. Dr. Andemariam is rated as an Experienced provider by MediFind in the treatment of Hemochromatosis. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

Her clinical research consists of co-authoring 48 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CT
Hospital Affiliations
John Dempsey Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

UNIVERSITY OF CONNECTICUT HEALTH CENTER
263 Farmington Ave, Farmington, CT 06030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
Enrollment Status: Completed
Publish Date: April 13, 2025
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
Sickle Cell Hemoglobinopathies and Bone Heath
Sickle Cell Hemoglobinopathies and Bone Heath
Enrollment Status: Active_not_recruiting
Publish Date: March 27, 2025
Intervention Type: Other
An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor)
An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor)
Enrollment Status: Terminated
Publish Date: November 25, 2024
Intervention Type: Drug
A Retrospective Data Collection and Analysis Study of Patients With Sickle Cell Disease (SCD) Who Have Been Treated With Oxbryta® (Voxelotor)
A Retrospective Data Collection and Analysis Study of Patients With Sickle Cell Disease (SCD) Who Have Been Treated With Oxbryta® (Voxelotor)
Enrollment Status: Completed
Publish Date: March 06, 2024
Intervention Type: Drug
A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease
A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease
Enrollment Status: Completed
Publish Date: November 21, 2023
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 4
View 5 Less Clinical Trials

48 Total Publications

The ASH Research Collaborative Sickle Cell Disease Research Network: Past, Present and Future.
The ASH Research Collaborative Sickle Cell Disease Research Network: Past, Present and Future.
Journal: Blood advances
Published: March 05, 2025
Similar Doctors
Distinguished in Hemochromatosis
Dr. Su H. Lim
Oncology | Hematology Oncology | Hematology
Distinguished in Hemochromatosis
Dr. Su H. Lim
Oncology | Hematology Oncology | Hematology

Yale University

800 Howard Ave, 
New Haven, CT 
 (30.6 miles away)
203-785-2140
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Su Lim is an Oncologist and a Hematologist Oncology provider in New Haven, Connecticut. Dr. Lim is rated as a Distinguished provider by MediFind in the treatment of Hemochromatosis. Her top areas of expertise are Hemochromatosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), Small Lymphocytic Lymphoma (SLL), and Chronic Lymphocytic Leukemia (CLL).

Distinguished in Hemochromatosis
Dr. Yelda Nouri
Hematology Oncology | Hematology | Oncology
Distinguished in Hemochromatosis
Dr. Yelda Nouri
Hematology Oncology | Hematology | Oncology

North Shore Hematology Oncology Associates PC

1500 Route 112, Suite 101, 
Port Jefferson Station, NY 
 (58.0 miles away)
631-751-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Yelda Nouri is a Hematologist Oncology specialist and a Hematologist in Port Jefferson Station, New York. Dr. Nouri is rated as a Distinguished provider by MediFind in the treatment of Hemochromatosis. Her top areas of expertise are Paget Disease of the Breast, Blood Clots, Hemochromatosis, and Childhood Iron Deficiency Anemia.

Distinguished in Hemochromatosis
Dr. Regina L. Jablonski
Hematology Oncology | Hematology | Oncology
Distinguished in Hemochromatosis
Dr. Regina L. Jablonski
Hematology Oncology | Hematology | Oncology

North Shore Hematology Oncology Associates PC

1500 Route 112, Suite 101, 
Port Jefferson Station, NY 
 (58.0 miles away)
631-751-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Regina Jablonski is a Hematologist Oncology specialist and a Hematologist in Port Jefferson Station, New York. Dr. Jablonski is rated as a Distinguished provider by MediFind in the treatment of Hemochromatosis. Her top areas of expertise are Blood Clots, Paget Disease of the Breast, Childhood Iron Deficiency Anemia, and Iron Deficiency Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Andemariam's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile